06-02-2020
PictureDesignSwiss / Shutterstock.com
US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Biogen, Mylan, Tecfidera, dimethyl fumarate, patent challenge, Patent Trial and Appeal Board, PTAB, obviousness, disease modifying drug, multiple sclerosis
